Pharmaceutical regulatory data, drug approvals & compliance tracking
Home › Drug Approvals › Endocrinology
Explore the latest data on endocrinology drug approvals. Our analytics platform processes thousands of data points daily to deliver reliable market intelligence. Market conditions change rapidly, and staying informed is crucial for making sound decisions. This page aggregates the most relevant data points and presents them in an easily digestible format.
For professional users, our API provides programmatic access to all data shown on this page. Rate limits apply based on your subscription tier. Contact us for enterprise pricing. Professional analysts frequently cite our data in market reports and strategic presentations. Our methodology has been validated by independent auditors and meets industry-standard accuracy requirements.
This page is part of the FDA News data platform, which offers comprehensive coverage across related categories. Navigate using the links above to explore other sections.
| Drug Name | Manufacturer | Approval Date | Indication | Type |
|---|---|---|---|---|
| Endoxumab | PharmaCo A | Mar 2026 | Advanced endocrinology | Biologic |
| Endotinib | PharmaCo B | Jan 2026 | Relapsed endocrinology | Small molecule |
| Endolizumab | PharmaCo C | Nov 2025 | Moderate endocrinology | Monoclonal Ab |
| Endostat | PharmaCo D | Sep 2025 | Chronic endocrinology | Oral |
| Endoparin | PharmaCo E | Jul 2025 | Acute endocrinology | Injectable |
Data updated continuously. Last refresh: May 11, 2026 14:30 UTC.
